According to Bloomberg sources, Boehringer Ingelheim is considering the sale of its U.S. Roxane Labs business, valued at as much as $2.4 billion.
Sources say the German drugmaker is working with Morgan Stanley on the possible sale of Ohio-based Roxane Labs, which is Boehringer's generic pharmaceutical business.
A Boehringer spokewoman would only confirm that the company is "exploring strategic options" when contacted by Bloomberg.
Read the Bloomberg release
